ONTX - Onconova Therapeutics (ONTX) - Narazaciclib Data Presented At Scientific Industry Conference

Onconova Presented Data At The Next Generation Kinase Inhibitors Summit. Onconova presented data from narazaciclib studies at an industry meeting attended by academic and corporate scientists. New data is not presented at this type of meeting, but speakers are able to present more information in greater detail than a medical meeting would typically allow. The communication with other scientists in the field also helps to establish a company's expertise, and can lead to future collaborations, clinical site participation, and corporate partnerships.Data Gave An Overview and Summary of Narazaciclib. Data was presented by Onconova's Director of Corporate Development, and a session was chaired by Onconova's CEO. These presentations gave data on narazaciclib's activity against CDK4, CDK6, and other intermediaries in a pathway that leads to cancer cell growth, proliferation, and metastasis. The data showed potent inhibition consistent with the efficacy as well as the low neutropenia seen in early clinical data.Narazaciclib Compares Well With Other CDK4/6 Inhibitors. The presentations also included data comparing narazaciclib to the three approved CDK4/6 inhibitor drugs. These data compared favorably, showing broader kinase inhibition and potent activity against proteins in the pathway. It also showed improved activity against factors leading to drug resistance, metastasis, and steps leading to cancer spread and invasion.Clinical Data Is Expected In 2H22. Narazaciclib is currently in two Phase 2 dose escalation trials. The first trial is in being conducted in China, following the 4-week dosing cycles for two of the approved CDK4/6 drugs. This trial is dosing its fifth cohort at 200 mg. The second trial is being conducted in the US, following the daily dosing used for the third approved CDK4/6 drug. This trial is currently in its fourth cohort of 160 mg doses. The data is expected to be announced in 2H22 and will be used to select a dose for the next trial.Conclusion. Presenting data and serving as Session Chairman helps Onconova establish its expertise in the field of kinase inhibition. This is important for future collaborations, including clinical trial site recruitment and corporate partnerships. The presentations provided a comprehensive summary of the available data, supporting our expectations for the clinical trials to show efficacy. We are reiterating our Outperform rating and $11 price target. Read More >>